Image

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations

Investigational Treatments for Hard-to-Treat RAS Mutation Conditions

Recruiting
18-85 years
All
Phase 2
  • Simplified description (AI rewritten)
  • Technical description (Original)

This study investigates conditions associated with RAS mutations. The purpose of this study is to explore the potential benefits of using leflunomide or a combination of MEK inhibitor and hydroxychloroquine for patients who have not responded to standard treatments.

The study evaluates the safety and effectiveness of these investigational treatments. It looks at how these treatments might work on the RAS pathway, which is important for the growth of certain types of cells.

  • Who can participate: Adults aged 18 and older with confirmed RAS mutations and a history of more than two lines of standard treatment may participate. Participants must have stage 4 metastatic disease.
  • Study details: Participants will receive either leflunomide or a combination of MEK inhibitor and hydroxychloroquine. A placebo may be used.
Print
Study details
    RAS Mutation
    Ras (Kras or Nras) Gene Mutation
    Colorectal Cancer Recurrent
    Pancreas Cancer
    Lung Cancer
    Melanoma
    Refractory Cancer

NCT06229340

N.N. Petrov National Medical Research Center of Oncology

8 April 2026

Contact a study center
Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.